Acomplia


Accomlia
Acomplia is a weight-loss medication developed by Sanofi-Aventis, a French pharmaceutical firm. Also known by its generic name Rimonabant, Acomplia works by blocking the CB1 receptor in the Endocannabinoid System (EC). The CB1 receptor is instrumental to the intake and regulation of food. When a patient begins taking Acomplia, their desire to eat excessively is suppressed. Along with weight loss, Acomplia has also shown to be very effective for smoking cessation.

Acomplia Pricelist


Medication Quantity Price Consult Fee Secure online Order form

Acomplia vs. Other Weight Loss Medications


Acomplia vs. Phentermine

Acomplia is as effective as Phentermine but with a number of ultimate advantages:

    - Acomplia doesn't contain controlled ingredients

    - Acomplia has no severe side effects and other negative reactions which Phentermine tends to cause

    - Acomplia is not habit-forming

    - Acomplia also helps reduce cardiovascular risk factors

    - Acomplia is very effective for treating smoking habit and alcohol abuse

    Acomplia vs. Xenical and Reductil. Compare side effects

    Some of the well-known side effects of other weight loss medications (such as Xenial and Reductil) include:

    • - Severe diarrhea
    • - High blood pressure
    • - Insomnia
    • - Constipation
    • - Dry mouth syndrome

    In the two year clinical trials, some side effects of Acomplia, although mild and short-lived, were noted. They include:

    • - Anxiety
    • - Irritability
    • - Nausea and vomiting
    • - Dizziness

    How Acomplia works. Long-term Weight Loss with Acomplia


    Acomplia prevents the brain from experiencing the satisfaction of a pleasurable activity (eating or smoking). It does this simply by preventing the EC substance from attaching to and stimulating the brain cells.

    Recent reports from researchers indicate that Acomplia with its active component Rimonabant can assist with long-term weight loss, up to two years. Studies revealed that patients taking Acomplia for more than two years experienced a steady loss of 16 pounds. More than one third of study participants lost 10% of their excess weight. It was also indicated that Acomplia assisted in the lowering of HDLs ("bad" cholesterol), increased LDLs ("good" cholesterol) and may be able to be used to help overcome drug and alcohol addiction.

    Acomplia is also a safe and effective weight loss drug for obese or overweight patients with other risk factors such as type 2 diabetes or dyslipidaemia - see the Body Mass Index for the definitions of what constitutes overweight or obese. In particular, Acomplia reduces the risk of heart disease and type 2 diabetes. It can also be used as an aid to quit smoking.

    Although Acomplia is a well-known name in Europe, the FDA office in charge of approving proposed medication names has decided to market Acomplia in the U.S. as Zimulti. This is because the FDA felt that the name Acomplia may be misleading to consumers, in that it may indicate that the patient would accomplish their weight loss goals.